MYC and hepatocellular carcinoma: Using c-Myc/E2F1 transgenic mouse model-driven liver cancer, the Wnt/β-catenin pathway, including its downstream targets, such as WISP1 and glutamine synthetase, has been activated, which was shown to confer cell growth in HCC [36].